ToxStrategies will be represented at the upcoming 31st annual meeting of the British Society of Toxicologic Pathology (BSTP) held jointly with the Association of Inhalation Toxicologists (AIT) in Alderley Edge, Cheshire, UK (November 10-11, 2016) by Dr. Marcie Wood. Dr. Wood will be presenting a US regulatory perspective on determination of adversity in inhalation toxicology studies.
Dr. Wood is a Senior Scientist in ToxStrategies’ Biopharmaceutical/Pharmaceutical Practice and has expertise assisting clients with issues related to nonclinical safety assessment of small molecule and biologic products, including general toxicology and inhalation toxicology. ToxStrategies’ scientists have worked at the FDA, as well as in the biopharmaceutical and pharmaceutical industries, and are uniquely suited to assist clients with complicated scientific, regulatory, and strategic challenges that arise during the nonclinical development of drug candidates.
Please contact Dr. Wood (email@example.com) if you would like to arrange to meet with her at BSTP/AIT.